What to do for Patients Who Delay Stem Cell Transplant
Release Date: January 30, 2014
Expiration Date: January 30, 2015
Expected time to complete this activity as designed: 30 minutes
There are no fees for participating in or receiving credit for this online activity.
The goal of treatment for active, symptomatic myeloma is to achieve a rapid, deep, and durable remission with improved performance status. The approaches used should not hinder future treatment options for the patient. In those who can tolerate it, high-dose melphalan and autologous stem cell transplant (ASCT), often followed by maintenance therapy, has been a standard strategy to achieve these goals, but it is a choice, not a necessity. The goal of any treatment plan is to provide the longest and best quality of life with the minimum burden of therapy. For some patients who may be qualified for high-dose chemotherapy with stem cell transplant support, the burden of therapy for this approach may be too great for the patient at the time therapy would normally be provided.
This activity is designed for physicians, pharmacists, physician assistants, and other health care professionals who have an interest in enhancing their clinical skills in the management of patients with multiple myeloma.
Upon completion of this educational activity, participants should be able to:
- Outline the rationale for high-dose treatment with ASCT support as part of primary therapy
- Identify current controversies and clinically unanswered questions regarding early vs delayed (salvage) ASCT
What to do for Patients Who Delay Stem Cell Transplant – Sergio Giralt, MD
Instructions for Participation and Credit
This activity is eligible for credit through January 30, 2015. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates may be printed immediately after successfully completing the post-test and activity evaluation.
Sergio A. Giralt, MD
Chief, Attending Physician
Adult Bone Marrow Transplant Service
Memorial Sloan-Kettering Cancer Center
New York, New York
Dr. Sergio Giralt received his medical degree from Universidad Central de Venezuela and completed his postgraduate internship at the University Hospital of Caracas. He also completed an internal medicine residency at Good Samaritan Hospital in Cincinnati, Ohio, and a postdoctoral fellowship in hematology and oncology at The University of Texas MD Anderson Cancer Center. Dr. Giralt is currently professor of medicine at Weill Cornell College of Medicine and the chief of the Adult Bone Marrow Transplant Service in the Division of Hematologic Oncology at Memorial Sloan-Kettering Cancer Center in New York City.
Board certified in internal medicine, hematology, and medical oncology, Dr. Giralt holds memberships in several professional societies, including the American College of Physicians, American Society of Clinical Oncology, American Society of Hematology, and the North American Society of Blood and Bone Marrow Transplantation, among others. He is a highly sought speaker, lecturer, and presenter who has published hundreds of research articles and abstracts in peer-reviewed literature. Additionally, he is an editorial reviewer for several journals including Blood, Bone Marrow Transplantation, Clinical Cancer Research, Journal of Clinical Oncology, and The Oncologist.
Dr. Giralt’s research focus is on stem cell transplantation for patients with blood disorders and improving treatments for older patients who have acute and chronic leukemia. The development of these less intense and less toxic regimens has changed the standard of care for older patients throughout the world.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of .5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for .5 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-14-384-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the Member Center on the home page of this site.
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Sergio Giralt has received honoraria related to formal advisory activities and as a consultant from Bioline, Celgene Corporation, Janssen Pharmaceuticals, Inc., Miltenyi Biotec, Novartis AG, Onyx, Seattle Genetics, Inc., and Spectrum Pharmaceuticals, Inc. He has received grant support related to research activities from Celgene and Onyx.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, executive director, and Eugene R. Tombler, PhD, FACME, medical director, oncology have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
Off-Label Disclosures/Investigational Disclosures
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
Dr. Giralt has indicated that he does intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.
Dr. Giralt has indicated that he does not intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.
MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at email@example.com.
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Millennium: The Takeda Oncology Company and Celgene Corporation.
©2014 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.